Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Patients With AIDS Syndrome
NCT00001120 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to find out why cancers develop in HIV-positive patients. Cancer is a leading cause of death in AIDS patients. Common cancers in HIV-infected patients include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), a cancer of the immune system. Risk factors include certain chemicals, viruses, and perhaps even anti-HIV drugs. Doctors would like to find out which risk factors are most important and how they relate to cancer in AIDS patients.
Conditions Studied
Study Locations (20)
California
- Willow Clinic — Menlo Park
- San Francisco Gen Hosp — San Francisco
- Marin County Specialty Clinic — San Rafael
- San Mateo AIDS Program / Stanford Univ — Stanford
- Stanford Univ Med Ctr — Stanford
New York
- SUNY / Erie County Med Ctr at Buffalo — Buffalo
- Bellevue Hosp / New York Univ Med Ctr — New York
- Mem Sloan - Kettering Cancer Ctr — New York
- St Mary's Hosp (Univ of Rochester/Infectious Diseases) — Rochester
- Univ of Rochester Medical Center — Rochester
Louisiana
- Charity Hosp / Tulane Univ Med School — New Orleans
- Tulane Univ School of Medicine — New Orleans
North Carolina
- Univ of North Carolina — Chapel Hill
- Duke Univ Med Ctr — Durham
Ohio
- Univ of Cincinnati — Cincinnati
- Case Western Reserve Univ — Cleveland
Hawaii
- Univ of Hawaii — Honolulu
Indiana
- Indiana Univ Hosp — Indianapolis
Maryland
- Johns Hopkins Hosp — Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001120
The ClinicalTrials.gov registry entry for NCT00001120 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00001120 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, New York, Louisiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00001120 about?
NCT00001120 is a clinical study titled "A Study of Patients With AIDS Syndrome". The purpose of this study is to find out why cancers develop in HIV-positive patients. Cancer is a leading cause of death in AIDS patients. Common cancers in HIV-infected patients include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), a cancer of the immune system. Risk factors include cer...
What is the current status of trial NCT00001120?
This trial is currently completed. The enrollment target is 5,000 participants.
What conditions does trial NCT00001120 study?
This clinical trial studies the following conditions: HIV Infections, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, AIDS-Related. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT00001120?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00001120 being conducted?
This trial has 20 study locations across California, Hawaii, Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.